Electrocardiographic assessments and cardiac events after fingolimod first dose - a comprehensive monitoring study

Jahr

2017

Autoren

Limmroth V, Ziemssen T, Lang M, Richter S, Wagner B, Haas J, Schmidt S, Gerbershagen K, Lassek C, Klotz L, Hoffmann O, Albert C, Schuh K, Baier-Ebert M, Wendt G, Schieb H, Hoyer S, Dechend R, Haverkamp W.

Verlag

BMC Neurol. 2017 Jan 18;17(1):11.

Link

https://doi.org/10.1186/s12883-016-0789-7

Electrocardiographic assessments and cardiac events after fingolimod first dose - a comprehensive monitoring study

RENEWED: A follow-up study of the opicinumab phase 2 RENEW study in participants with acute optic neuritis

Patients with relapsing-remitting multiple sclerosis show accelerated whole brain volume and thalamic volume loss early in disease

Challenges and implications of anti-JCV antibody serology variability among different assays in natalizumab treatment: A call for standardization and transparency in clinical practice

MS brain health quality standards: a survey on the reality in clinical practice in Germany

Best supportive care for patients with primary progressive multiple sclerosis (PPMS) in Germany prior to ocrelizumab treatment: Final results from the RETRO PPMS study